Burgeoning problems of antimicrobial resistance dictate that new solutions be developed to combat old foes. Use of lytic bacteriophages (phages) for the treatment of drug-resistant bacterial infections is one approach that has gained significant traction in recent years. Fueled by reports of experimental phage therapy cases with very positive patient outcomes, several early-stage clinical trials of therapeutic phage products have been launched in the United States. Eventual licensure enabling widespread access to phages is the goal; however, new paths to regulatory approval and mass-market distribution, distinct from those of small-molecule antibiotics, must be forged first. This review highlights unique aspects related to the clinical use of phages, including advantages to be reaped as well as challenges to be overcome.

中文翻译：

---

二十一世纪的噬菌体疗法：面对抗生素时代的衰落；是时候进入噬菌体时代了？

抗菌素耐药性的新兴问题要求开发新的解决方案以对抗老对手。使用裂解性噬菌体（噬菌体）来治疗耐药性细菌感染是近年来获得极大关注的一种方法。在实验性噬菌体治疗病例的患者预后非常好的报道的推动下，美国已启动了几种治疗性噬菌体产品的早期临床试验。目标是最终获得许可，以使噬菌体得以广泛使用。但是，必须首先锻造出与小分子抗生素不同的新的监管批准和大众市场分销途径。这篇综述重点介绍了与噬菌体临床使用相关的独特方面，包括要收获的优势和要克服的挑战。